EXHIBIT 10.14
 XXXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT
WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
 EXECUTION COPY
 LICENSE, DEVELOPMENT AND COMMERCIALIZATION
AGREEMENT
 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Agreement Effective Date IMPAX LABORATORIES, INC., Impax GLAXO GROUP LIMITED GSK Party Parties
 RECITALS
 Whereas,
 Whereas,
 Whereas,
 Whereas, Supply Agreement
 Now, Therefore ,
 ARTICLE 1
 DEFINITIONS
 1.1 Acquiror
 1.2 Additional GSK Modifications
 1.3 Affiliate




---



##### 



1.4 Alliance Manager
 1.5 Bankruptcy
 1.6 Bankruptcy Code
 1.7 Bioequivalence Study
 1.8 Business Day
 1.9 Change of Control XXXXXX
 1.10 Claims
 1.11 CMC Information
 1.12 Commercialization Commercialize Commercializing provided however
  2.




---



##### 



1.13 Commercialization Plan
 1.14 Commercially Reasonable Efforts
 1.15 Competing Product
 1.16 Confidential Information Confidentiality Agreement
 1.17 Control
 1.18 Courts
  3.




---



##### 



1.19 CPI-U
 1.20 Develop Development provided however
 1.21 Development Costs
 1.22 Development Plan
 1.23 Dispute
 1.24 Dollar
 1.25 EMA
 1.26 EU European Union
 1.27 Executive Officers
 1.28 Expert
 1.29 FD&C Act
 1.30 FDA
  4.




---



##### 



1.31 Field
 1.32 First Commercial Sale
 1.33 FTE
 1.34 FTE Rate
 1.35 GAAP
 1.36 Generic Product
  5.




---



##### 



1.37 GCP Good Clinical Practices
 1.38 GLP Good Laboratory Practices
 1.39 Governmental Authority
 1.40 GSK Indemnitees
 1.41 GSK Know-How
 1.42 GSK Modifications
 1.43 GSK Patent
 1.44 GSK Prosecuted Patents
 1.45 GSK Technology
  6.




---



##### 



1.46 GSK Withholding Tax Action
 1.47 ICH
 1.48 IFRS
 1.49 Impax Indemnitees
 1.50 Impax Know-How
 1.51 Impax Patents
 1.52 Impax Prosecuted Patents
 1.53 Impax Technology
 1.54 Improved Product XXXXXX XXXXXX
 1.55 Indemnified Party
 1.56 Indemnifying Party
 1.57 Indication
  7.




---



##### 



1.58 Information
 1.59 Infringement
 1.60 INN
 1.61 Joint Inventions
 1.62 Joint Patents
 1.63 Joint Patent Committee JPC
 1.64 Joint Steering Committee JSC
 1.65 Laws
 1.66 XXXXXX XXXXXX
 1.67 Licensed Product
 1.68 Licensed Territory
 1.69 Major Market Country XXXXXX
 1.70 Manufacture Manufacturing
  8.




---



##### 



1.71 Marketing Authorization Application MAA
 1.72 NDA et seq.
 1.73 Net Sales
 (a) provided however
 (b)
 (c)
 (d)
 (e)
   9.




---



##### 



de minimis
  1.74 Neuroscience Business
 1.75 Option
 1.76 Option Exercise Fee
 1.77 Original Product
 1.78 Other Shared Development Activities
 1.79 Party Sublicense Agreement
 1.80 Patents
 1.81 Pharmacovigilance Agreement
 1.82 XXXXXX XXXXXX
 1.83 Phase III Clinical Trial
  10.




---



##### 



1.84 Pivotal Phase III Trials
 1.85 Pricing Approval Pricing Decision
 1.86 Product Marks
 1.87 Prosecution and Maintenance Prosecute and Maintain
 1.88 Regulatory Approval
  11.




---



##### 



1.89 Regulatory Approval Application
 1.90 Regulatory Authority
 1.91 Regulatory Exclusivity
 1.92 Regulatory Submissions
 1.93 Reimbursement Study
 1.94 Remedial Action
 1.95 Royalty Term
 1.96 Sale of the Neuroscience Business
 1.97 SEC
 1.98 Selected Claim
 1.99 Selected Major Market XXXXXX
 1.100 Senior Patent Counsel
 1.101 Sensitive Information
 1.102 Serious Adverse Event
 1.103 Sole Inventions
 1.104 Subcommittee
  12.




---



##### 



1.105 Successful Completion Successfully Completing
 1.106 Supply Agreement
 1.107 Term
 1.108 Third Party
 1.109 U.S
 1.110 Valid Claim
 1.111 Wind-down Period
 ARTICLE 2
 LICENSES AND OPTION
 2.1 Licenses to GSK under Impax Technology.
 (a) Development License to GSK
  13.




---



##### 



(b) Commercial License To GSK
 (c) Clarification Regarding Manufacturing Data
 (d) Impax Retained Rights
 (e) Sublicense Rights of GSK. provided however provided however
 (f) Covenant Not to Sue
  14.




---



##### 



2.2 License to Impax under GSK Technology
 2.3 Negative Covenant; General Sublicense Terms
 (a)
 (b) Party Sublicense Agreement
 (i)
 (ii)
 (iii)
 (iv)
 (v)
 (vi)
  15.




---



##### 



(vii)
 (viii)
 (ix)
 2.4 Option.
 (a) Grant Option
 (b) Exercise; Expiration XXXXXX XXXXXX XXXXXX
 (c) Option Exercise Fee XXXXXX XXXXXX Option Exercise Fee
 (d) After Payment of Option Exercise Fee Licensed Product XXXXXX XXXXXX provided however
  16.




---



##### 



2.5 No Implied Licenses
 2.6 Exclusivity
 (a) XXXXXX XXXXXX Competing Product provided however
 (i) XXXXXX provided however
 (ii)
 (iii) XXXXXX
 (b)
 (i)
  17.




---



##### 



(ii)
 (iii) XXXXXX
 (iv) XXXXXX XXXXXX provided,
however XXXXXX
 (c)
 ARTICLE 3
 GOVERNANCE
 3.1 Alliance Managers Alliance
Manager
 3.2 Joint Steering Committee.
 (a) Formation and Role Joint Steering Committee JSC
 (i)
 (ii)
 (iii)
  18.




---



##### 



(iv)
 (v)
 (vi) Selected Claim
 (vii)
  (b) Subcommittee(s). Subcommittee
 (c) Members
 (d) Meetings provided however
  19.




---



##### 



(e) Decision Making
 (i) XXXXXX XXXXXX
 (ii) Expert XXXXXX
 (iii) Patent Expert XXXXXX
 (iv)
   20.




---



##### 



3.3 Joint Patent Committee Joint Patent Committee JPC Senior Patent Counsel XXXXXX
 ARTICLE 4
 PRODUCT DEVELOPMENT
 4.1 Overview
  21.




---



##### 



4.2 Development Responsibilities
 (a) Impax Development Responsibilities.
 (i) GSK Modifications
 (ii) Additional GSK Modifications
 (iii) Other Shared Development Activities
  22.




---



##### 



(iv)
 (v)
 (b) GSK Development Responsibilities.
 (i)
 (ii)
 (iii)
 4.3 Development Plan.
 (a) General Development Plan XXXXXX XXXXXX
  23.




---



##### 



(b) Amendments XXXXXX
 (c) Performance
 4.4 Development Costs XXXXXX XXXXXX XXXXXX XXXXXX
  24.




---



##### 



4.5 Diligence XXXXXX XXXXXX XXXXXX provided however provided further XXXXXX XXXXXX
 (a) XXXXXX
 (b) XXXXXX
 (c) XXXXXX
 (d) XXXXXX
 (e) XXXXXX
 XXXXXX XXXXXX
 4.6 Mutual Data Exchange and Use
 4.7 Development Reports XXXXXX
 4.8 Development Records
  25.




---



##### 



4.9 Compliance with Laws
 4.10 Transfer of Know-How
 4.11 Impaxs Other Licensees
 ARTICLE 5
 REGULATORY MATTERS
 5.1 Regulatory Responsibilities in the Licensed Territory.
 (a) provided however XXXXXX
  26.




---



##### 



(b)
 (c)
 (d)
 5.2 Regulatory Responsibilities outside the Licensed Territory.
 (a)
  27.




---



##### 



(b)
 (c)
 5.3 Regulatory Costs
 5.4 Rights of Reference to Regulatory Submissions
  28.




---



##### 



5.5 Cooperation and Consistency
 (a)
 (b)
 5.6 Notification of Threatened Action
 5.7 Adverse Event Reporting and Safety Data Exchange.
 (a) Pharmacovigilance
Agreement
  29.




---



##### 



(b) Adverse Event Serious Adverse Event i e
 5.8 Remedial Actions Remedial Action
 ARTICLE 6
 COMMERCIALIZATION
 6.1 Overview of Commercialization in the Licensed Territory
  30.




---



##### 



6.2 Commercialization Plan for Licensed Territory.
 (a) General Commercialization Plan XXXXXX XXXXXX XXXXXX
 (b) Initial Plan and Amendments
 6.3 Pricing provided however XXXXXX
 6.4 Commercial Diligence.
 (a) XXXXXX provided however XXXXXX XXXXXX XXXXXX provided,
however XXXXXX XXXXXX
  31.




---



##### 



(b) Failure to Launch
 XXXXXX XXXXXX XXXXXX XXXXXX
 XXXXXX XXXXXX XXXXXX provided however XXXXXX
 XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX provided however XXXXXX provided, further XXXXXX XXXXXX
  32.




---



##### 



6.5 Cross-Territorial Restrictions
 6.6 Reports
 ARTICLE 7
 COMPENSATION
 7.1 Upfront Payment
 7.2 Reimbursement of Development Costs.
 (a)
 (b) XXXXXX XXXXXX
  33.




---



##### 



(c) XXXXXX XXXXXX provided however
 (d)
 (e)
 7.3 Milestone Payments.
 (a) XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
 (b) XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
 (c) XXXXXX XXXXXX XXXXXX XXXXXX
  34.




---



##### 



(d) XXXXXX XXXXXX
 (i) XXXXXX XXXXXX XXXXXX XXXXXX
 (ii) XXXXXX XXXXXX XXXXXX
  (e) Additional Indications XXXXXX XXXXXX XXXXXX
 (f) Clarification provided however
 7.4 Royalties and XXXXXX Payments.
 (a) Royalty Rates
 Annual Net Sales of all Licensed Products in the Licensed Territory
    
    Royalty RateFor that portion of annual Net Sales less than or equal to XXXXXXDollars ($XXXXXX)
    
    XXXXXX
    %For that portion of annual Net Sales greater than XXXXXX
Dollars ($XXXXXX) but less than or equal to XXXXXXDollars
($XXXXXX)
    
    XXXXXX
    %For that portion of annual Net Sales greater than XXXXXX
Dollars ($XXXXXX)
    
    XXXXXX
    %
  35.




---



##### 



(b) Royalty Term Royalty Term
 (c) Royalty Reductions.
 (i) XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
  36.




---



##### 



(ii) XXXXXX XXXXXX
 (iii) XXXXXX XXXXXX
 (iv) XXXXXX XXXXXX
 (d) Royalty Adjustment due to the Transfer Price of a Licensed Product. XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
  37.




---



##### 



(e) XXXXXX Payments XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
 XXXXXX
    
    XXXXXX PaymentXXXXXX
    
    XXXXXXDollars ($XXXXXX
    )XXXXXX
    
    XXXXXXDollars ($XXXXXX
    )XXXXXX
    
    XXXXXXDollars ($XXXXXX
    )XXXXXX
    
    XXXXXXDollars ($XXXXXX
    )
 (f) Royalty Reports and Payments XXXXXX
 7.5 Blocked Currency
  38.




---



##### 



7.6 Foreign Exchange
 7.7 Payment Method; Late Payments
 7.8 Accounting; Records; Audits IFRS GAAP
  39.




---



##### 



7.9 Taxes
 (a) Taxes on Income; Withholding
 (b) Tax on Income
 (c) Tax Cooperation
 (d) Taxes Resulting From GSK Action GSK Withholding Tax Action
  40.




---



##### 



ARTICLE 8
 INTELLECTUAL PROPERTY MATTERS
 8.1 Ownership of Inventions Sole Inventions Joint Inventions Joint Patents
 8.2 Disclosure of Inventions
 8.3 Prosecution of Patents.
 (a) Impax Prosecuted Patents Impax Prosecuted Patents
  41.




---



##### 



(b) GSK Prosecuted Patents.
 (i) GSK Prosecuted Patents
 (ii)
 (iii) XXXXXX XXXXXX
 (c) Cooperation
 (d) Patent Term Extension
  42.




---



##### 



8.4 Enforcement of Impax Patents and Joint Patents.
 (a) Notification Infringement
 (b) Enforcement Rights
 (c) Collaboration
 (d) Settlement
 (e) Expenses and Recoveries XXXXXX provided however XXXXXX
  43.




---



##### 



8.5 Enforcement of GSK Patents
 8.6 Patents Licensed From Third Parties
 8.7 Infringement of Third Party Rights in the Licensed Territory provided however
 8.8 Patent Marking
 8.9 Trademarks Product Marks provided however
  44.




---



##### 



8.10 International Nonproprietary Name INN
 ARTICLE 9
 REPRESENTATIONS AND WARRANTIES; COVENANTS
 9.1 Mutual Representations and Warranties
 (a) Corporate Existence
 (b) Corporate Power, Authority and Binding Agreement
 9.2 Additional Representations and Warranties of Impax
 (a) Title; Encumbrances
 (b) Notice of Infringement or Misappropriation
 (c) Non-Infringement of Third Party Rights
 (d) No Proceeding
  45.




---



##### 



(e) Other Agreements
 (f) Certain Other Arrangements
 (g) Prosecution of Impax Patents
 9.3 Additional Representations and Warranties of GSK
 9.4 Mutual Covenants.
 (a) No Debarment
 (b) Conduct of Activities
 (c) Compliance
  46.




---



##### 



9.5 Additional Covenants of Impax XXXXXX
 (a) XXXXXX
 (b) XXXXXX
 (c) XXXXXX
 (d) XXXXXX
 (e) XXXXXX
 XXXXXX
 9.6 Disclaimer
 9.7 No Other Representations or Warranties
 ARTICLE 10
 INDEMNIFICATION
 10.1 Indemnification by Impax GSK Indemnitees Claims
  47.




---



##### 



10.2 Indemnification by GSK Impax Indemnitees
 10.3 Indemnification Procedures Indemnified Party Indemnifying Party provided however
 10.4 Limitation of Liability
  48.




---



##### 



10.5 Supply Agreement
 10.6 Insurance
 ARTICLE 11
 CONFIDENTIALITY
 11.1 Confidentiality
 (a)
 (b)
  49.




---



##### 



(c)
 (d)
 (e)
 11.2 Authorized Disclosure
 (a)
 (b) provided however
 (c) provided however
 (d)
   50.




---



##### 



11.3 Technical Publication.
 (a)
 (b)
 11.4 Publicity.
 (a)
 (b)
 (c) provided however
  51.




---



##### 



(d) SEC provided however
 11.5 Equitable Relief
 ARTICLE 12
 TERM AND TERMINATION
 12.1 Term Term provided however XXXXXX Impax Manufacturing Technology
  52.




---



##### 



12.2 Unilateral Termination by GSK.
 (a)
 (b)
 12.3 Unilateral Termination by Impax. XXXXXX XXXXXX XXXXXX provided however XXXXXX XXXXXX
 12.4 Termination Due to Termination of the Supply Agreement
 12.5 Termination for Breach.
 (a)
 (b) XXXXXX
 (c) XXXXXX XXXXXX provided, however
  53.




---



##### 



12.6 Termination for Insolvency.
 (a) Bankruptcy
 (b) Bankruptcy Code
 12.7 Effect of Termination i.e.
 (a) Regulatory Submissions; Data
  54.




---



##### 



(b) GSK License
 (c) Trademarks provided however
 (d) Transition Assistance.
 (i)
 (ii) XXXXXX XXXXXX XXXXXX XXXXXX
 (iii) XXXXXX XXXXXX Wind-down Period provided however
  55.




---



##### 



(e) Ongoing Clinical Trials.
 (i)
 (ii) XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX
 (iii)
 (iv)
  56.




---



##### 



(v)
 (f) Inventories XXXXXX XXXXXX
 12.8 Survival
 ARTICLE 13
 DISPUTE RESOLUTION
 13.1 Disputes Dispute Executive Officers
  57.




---



##### 



13.2 Jurisdiction; Governing Law Courts
 13.3 Patent and Trademark Disputes
 ARTICLE 14
 MISCELLANEOUS
 14.1 Entire Agreement; Amendment
  58.




---



##### 



14.2 Force Majeure
 14.3 Notices
 If to Impax:
    
    Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward, CA 94544
Attn: President, Impax Pharmaceuticals
Fax: 510-972-7756With copies to (which shall not constitute notice):
    
    Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward, CA 94544
Attn: Legal Department
Fax: 510-972-7756
Cooley LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
Attn: Marya A. Postner, Ph.D.
Fax: (650) 849-7400
  59.




---



##### 



If to GSK:
    
    Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue
Greenford, Middlesex
UB6 0NN, England
Attn: Company Secretary
Fax: 44 20 8 047 6904With a copy to (which shall not constitute notice):
    
    GlaxoSmithKline, LLC
2301 Renaissance Boulevard
Mail Code RN0220
King of Prussia, PA 19406Attn: Vice President and Associate General Counsel, LegalOperations  Business DevelopmentFax: 610-787-7084
 14.4 No Strict Construction; Headings
 14.5 Assignment Acquiror
  60.




---



##### 



14.6 Change of Control of Impax
 (a) XXXXXX XXXXXX XXXXXX Sensitive Information
 (b) provided however XXXXXX
 14.7 Performance by Affiliates
 14.8 Further Actions
  61.




---



##### 



14.9 Severability
 14.10 No Waiver
 14.11 Independent Contractors
 14.12 English Language
 14.13 Counterparts
  62.




---



##### 



In Witness Whereof,
 Glaxo Group Limited
    
    
    
    Impax Laboratories, Inc.By:
    
    /s/ Paul Williamson
    
    
    
    By:
    
    /s/ Larry HsuName:
    
    Paul Williamson
    
    
    
    
    
    Name: Larry HsuTitle:
    
    Authorised Signatory
For and on behalf of
Edinburgh Pharmaceutical
Industries Limited
Corporate Director
    
    
    
    
    
    Title: President & CEO




---



##### 



EXHIBIT A
 PIVOTAL PHASE III TRIALS AND GSK MODIFICATIONS
 Phase 3, Study 1: IPX066 B08-05
 Title: A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with
Parkinsons disease
  XXXXXX
 XXXXXX
 Phase 3 Study 2: IPX066 B09-02
 Title: A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinsons Disease
Subjects
 XXXXXX
 XXXXXX
 XXXXXX
 Phase 3 Study 3: IPX066 B09-06
 Title: A Study to Compare IPX066 and carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinsons
Disease
 XXXXXX




---



##### 



CONFIDENTIAL
 EXHIBIT B
 INITIAL DEVELOPMENT PLAN
 XXXXXX
 XXXXXX




---



##### 



EXHIBIT C
 JOINT PRESS RELEASE




---



##### 



PRESS RELEASE
    
    (GLAXOSMITHKLINE LOGO)
 
 GlaxoSmithKline and Impax Pharmaceuticals Enter Global Agreement to Develop and Commercialize
a late stage compound for Parkinsons Disease
 London & Hayward, Calif., December XX, 2010  GlaxoSmithKline (GSK) and Impax
Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax)




---



##### 



PRESS RELEASE
    
    (GLAXOSMITHKLINE LOGO)
 
 About IPX066
    About Parkinsons Disease
  About Impax Laboratories, Inc.
 www.impaxlabs.com
 Impax Laboratories, Inc: Company Contact:      www.impaxlabs.com




---



##### 



PRESS RELEASE
    
    (GLAXOSMITHKLINE LOGO)
 
 GlaxoSmithKline www.gsk.com
 GlaxoSmithKline Enquiries:UK Media enquiries:
    
    David Mawdsley
    
    
    (020) 8047 5502Claire Brough
    
    
    (020) 8047 5502Stephen Rea
    
    
    (020) 8047 5502Alexandra Harrison
    
    
    (020) 8047 5502Jo Revill
    
    
    (020) 8047 5502US Media enquiries:
    
    Nancy Pekarek
    
    
    (919) 483 2839Mary Anne Rhyne
    
    
    (919) 483 2839Kevin Colgan
    
    
    (919) 483 2839Jennifer Armstrong
    
    
    (919) 483 2839European Analyst/Investor enquiries:
    
    Sally Ferguson
    
    
    (020) 8047 5543Gary Davies
    
    
    (020) 8047 5503Ziba Shamsi
    
    
    (020) 8047 3289US Analyst/ Investor enquiries:
    
    Tom Curry
    
    
    (215) 751 5419Jen Hill Baxter
    
    
    (215) 751 7002
 Safe Harbor statement under the Private Securities Litigation Reform
Act of 1995:
  GSKs cautionary statement regarding forward-looking statements




---



##### 



Schedule 1.34
 FTE Rates
 XXXXXX
 XXXXXX




---



##### 



Schedule 1.51  List of Impax Patents
 Patent Family A
 Filing/SubmissionAppl. No.
    
    Country/Region
    
    Date
    
    Priority Date
    
    Priority Application
    
    Status10/241,837
    
    United States
    
    September 12, 2002
    
    May 29, 2002
    
    USSN 10/158,412
    
    Issued(USPN 7,094,427)03756204.8
    
    Europe
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Pending2003/247409
    
    Australia
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Granted(AUPN 2003247409)2,486,859
    
    Canada
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Granted(CAPN 2,486,859)5107265.8
    
    Hong Kong
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Pending164856
    
    Israel
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Granted(ILPN 164856)2004-508790
    
    Japan
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Pending10-2004-7019167
    
    South Korea
    
    May 23, 2003
    
    May 29, 2002
    
    PCT/US03/016391
    
    Pending




---



##### 



Schedule 1.51  List of Impax Patents (cont.)
 Patent Family B
 Filing/SubmissionAppl. No.
    
    Country/Region
    
    Date
    
    Priority Date
    
    Priority Application
    
    Status12/599,668
    
    United States
    
    November 10, 2009
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending2008343787
    
    Australia
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending2,711,014
    
    Canada
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending200880122755.1
    
    China
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending08866933.8
    
    Europe
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending206756
    
    Israel
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending1350/MUMN/2010
    
    India
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending100114775
    
    Japan
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending10-2010-7016189
    
    South Korea
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    PendingMX/a2010/007207
    
    Mexico
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending586870
    
    New Zealand
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    PendingNot yet known
    
    Singapore
    
    December 26, 2008
    
    December 28, 2007
    
    PCT/US08/014080
    
    Pending